Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262001 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT01262001 is a Phase 2 study that has completed, run by Kyntra Bio. The registered enrollment target is 90 participants.
The verdict
NCT01262001, a Phase 2 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.
Interventions
- DRUG FG-3019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2011-03 |
| Est. Completion | 2017-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262001
The ClinicalTrials.gov registry entry for NCT01262001 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FG-3019 is the first listed.
NCT01262001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01262001 about?
NCT01262001 is a clinical study titled "Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis". To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.
What is the current status of trial NCT01262001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2011-03. Estimated completion is 2017-06-21.
What interventions are being tested in trial NCT01262001?
The interventions under investigation include: FG-3019 (DRUG).
Who is sponsoring clinical trial NCT01262001?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.